Published in J Control Release on October 29, 2013
Integrated PET/MRI for planning navigated biopsies in pediatric brain tumors. Childs Nerv Syst (2014) 0.85
Understanding Heterogeneity and Permeability of Brain Metastases in Murine Models of HER2-Positive Breast Cancer Through Magnetic Resonance Imaging: Implications for Detection and Therapy. Transl Oncol (2015) 0.78
In vitro treatment of melanoma brain metastasis by simultaneously targeting the MAPK and PI3K signaling pathways. Int J Mol Sci (2014) 0.78
Evaluating Changes to Blood-Brain Barrier Integrity in Brain Metastasis over Time and after Radiation Treatment. Transl Oncol (2016) 0.76
A Novel Nanoprobe for Multimodal Imaging Is Effectively Incorporated into Human Melanoma Metastatic Cell Lines. Int J Mol Sci (2015) 0.75
Dynamic contrast-enhanced MR imaging pharmacokinetic parameters as predictors of treatment response of brain metastases in patients with lung cancer. Eur Radiol (2017) 0.75
SENSE: sensitivity encoding for fast MRI. Magn Reson Med (1999) 29.55
Generalized autocalibrating partially parallel acquisitions (GRAPPA). Magn Reson Med (2002) 20.68
Homodyne detection in magnetic resonance imaging. IEEE Trans Med Imaging (1991) 3.70
Heterogeneous blood-tumor barrier permeability determines drug efficacy in experimental brain metastases of breast cancer. Clin Cancer Res (2010) 3.35
The blood-brain barrier and cancer: transporters, treatment, and Trojan horses. Clin Cancer Res (2007) 3.04
Temporary disruption of the blood-brain barrier by use of ultrasound and microbubbles: safety and efficacy evaluation in rhesus macaques. Cancer Res (2012) 2.60
Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival. J Neurosurg (2012) 2.28
The seed and soil hypothesis: vascularisation and brain metastases. Lancet Oncol (2002) 2.27
The biology of brain metastases-translation to new therapies. Nat Rev Clin Oncol (2011) 2.16
Multidisciplinary management of brain metastases. Oncologist (2007) 2.15
Increased permeability of the blood-brain barrier to chemotherapy in metastatic brain tumors: establishing a treatment paradigm. J Clin Oncol (2007) 2.09
Brain metastases as preventive and therapeutic targets. Nat Rev Cancer (2011) 2.05
The vascular basement membrane as "soil" in brain metastasis. PLoS One (2009) 1.95
Astrocytes upregulate survival genes in tumor cells and induce protection from chemotherapy. Neoplasia (2011) 1.78
The biology of metastasis to a sanctuary site. Clin Cancer Res (2007) 1.72
Capturing changes in the brain microenvironment during initial steps of breast cancer brain metastasis. Am J Pathol (2010) 1.68
In vivo animal models for studying brain metastasis: value and limitations. Clin Exp Metastasis (2013) 1.52
Contribution of carrier-mediated transport systems to the blood-brain barrier as a supporting and protecting interface for the brain; importance for CNS drug discovery and development. Pharm Res (2007) 1.43
Biodistribution of radiolabeled, formulated gadopentetate, gadoteridol, gadoterate, and gadodiamide in mice and rats. Invest Radiol (1995) 1.41
A modular system for the synthesis of multiplexed magnetic resonance probes. J Am Chem Soc (2011) 1.40
Quantitative magnetic resonance and optical imaging biomarkers of melanoma metastatic potential. Proc Natl Acad Sci U S A (2009) 1.38
Magnitude of enhanced permeability and retention effect in tumors with different phenotypes: 89Zr-albumin as a model system. J Nucl Med (2011) 1.34
Differential permeability of the blood-brain barrier in experimental brain metastases produced by human neoplasms implanted into nude mice. Am J Pathol (1992) 1.31
Surgery and radiotherapy compared with gamma knife radiosurgery in the treatment of solitary cerebral metastases of small diameter. J Neurosurg (1999) 1.29
Clinical applications of 7 T MRI in the brain. Eur J Radiol (2011) 1.27
The biology of melanoma brain metastasis. Cancer Metastasis Rev (1999) 1.21
The brain microenvironment and cancer metastasis. Mol Cells (2010) 1.21
Pharmacokinetic considerations in the treatment of CNS tumours. Clin Pharmacokinet (2006) 1.20
Brain metastases: pathobiology and emerging targeted therapies. Acta Neuropathol (2012) 1.19
Pharmacokinetics of Gadomer-17, a new dendritic magnetic resonance contrast agent. MAGMA (2001) 1.18
Brain metastasis: opportunities in basic and translational research. Cancer Res (2009) 1.17
Incidence and distribution of experimental metastases in mutant mice with defective organ microenvironments (genotypes Sl/Sld and W/Wv). Cancer Res (1992) 1.14
In vivo characterization of changing blood-tumor barrier permeability in a mouse model of breast cancer metastasis: a complementary magnetic resonance imaging approach. Invest Radiol (2011) 1.14
Changes of the blood-brain barrier in experimental metastatic brain tumors. J Neurosurg (1983) 1.13
Using high-resolution MR imaging at 7T to evaluate the anatomy of the midbrain dopaminergic system. AJNR Am J Neuroradiol (2010) 1.13
Incidence and time trends of brain metastases admissions among breast cancer patients in Sweden. Br J Cancer (2012) 1.12
Transmigration of melanoma cells through the blood-brain barrier: role of endothelial tight junctions and melanoma-released serine proteases. PLoS One (2011) 1.11
Uptake of ANG1005, a novel paclitaxel derivative, through the blood-brain barrier into brain and experimental brain metastases of breast cancer. Pharm Res (2009) 1.10
Noninvasive imaging of the functional effects of anti-VEGF therapy on tumor cell extravasation and regional blood volume in an experimental brain metastasis model. Clin Exp Metastasis (2009) 1.10
Molecular MRI enables early and sensitive detection of brain metastases. Proc Natl Acad Sci U S A (2012) 1.10
Imaging of adult astrocytic brain tumours with 7 T MRI: preliminary results. Eur Radiol (2009) 1.08
The treatment of brain metastases in melanoma patients. Cancer Treat Rev (2004) 1.08
The pathogenesis and treatment of brain metastases: a comprehensive review. Crit Rev Oncol Hematol (2004) 1.06
Spontaneously T1-hyperintense lesions of the brain on MRI: a pictorial review. Curr Probl Diagn Radiol (2003) 1.01
Reduced field-of-view MRI with two-dimensional spatially-selective RF excitation and UNFOLD. Magn Reson Med (2005) 1.01
Clinical evaluation of targeting accuracy of gamma knife radiosurgery in trigeminal neuralgia. Int J Radiat Oncol Biol Phys (2007) 0.97
Peptide targeted tripod macrocyclic Gd(III) chelates for cancer molecular MRI. Biomaterials (2013) 0.96
Preclinical approaches to study the biology and treatment of brain metastases. Semin Cancer Biol (2010) 0.95
Longitudinal investigation of permeability and distribution of macromolecules in mouse malignant transformation using PET. Clin Cancer Res (2010) 0.94
Drug delivery strategies for the treatment of malignant gliomas. Int J Pharm (2012) 0.94
Automated tracking of nanoparticle-labeled melanoma cells improves the predictive power of a brain metastasis model. Cancer Res (2013) 0.94
Microenvironment determinants of brain metastasis. Cell Biosci (2011) 0.93
Differential microstructure and physiology of brain and bone metastases in a rat breast cancer model by diffusion and dynamic contrast enhanced MRI. Clin Exp Metastasis (2011) 0.92
A novel brain metastases model developed in immunodeficient rats closely mimics the growth of metastatic brain tumours in patients. Neuropathol Appl Neurobiol (2011) 0.92
Stability and biodistribution of a biodegradable macromolecular MRI contrast agent Gd-DTPA cystamine copolymers (GDCC) in rats. Pharm Res (2010) 0.91
Brain metastasis of small cell lung carcinoma: comparison of Gd-DTPA enhanced magnetic resonance imaging and enhanced computerized tomography. Jpn J Clin Oncol (1994) 0.83
Angiogenesis and blood-brain barrier breakdown modulate CT contrast enhancement: an experimental study in a rabbit brain-tumor model. AJR Am J Roentgenol (1989) 0.83
The role of surgery, radiosurgery and whole brain radiation therapy in the management of patients with metastatic brain tumors. Int J Surg Oncol (2011) 0.82
Combining temozolomide with other antitumor drugs and target-based agents in the treatment of brain metastases: an unending quest or chasing a chimera? Expert Opin Investig Drugs (2011) 0.82
In vivo Modeling and Molecular Characterization: A Path Toward Targeted Therapy of Melanoma Brain Metastasis. Front Oncol (2013) 0.81
Luciferase: a sensitive and quantitative probe for blood-brain barrier disruption. J Neurosci Methods (1998) 0.81
Bioluminescence imaging of invasive intracranial xenografts: implications for translational research and targeted therapeutics of brain tumors. Neurosurg Rev (2010) 0.81
Molecular aspects of breast cancer metastasis to the brain. Genet Res Int (2011) 0.79
Heading in a new direction: drug permeability in breast cancer brain metastasis. Clin Cancer Res (2010) 0.78
Improved PET imaging of tumors in mice using a novel (18) F-folate conjugate with an albumin-binding entity. Mol Imaging Biol (2013) 0.77
Physicochemical properties, pharmacokinetics, and biodistribution of gadoteridol injection in rats and dogs. Acad Radiol (1995) 0.76
Combining stereotactic radiosurgery and systemic therapy for brain metastases: a potential role for temozolomide. Front Oncol (2012) 0.76
The magnitude of radiation force on ultrasound contrast agents. J Acoust Soc Am (2002) 2.38
Ultrasound contrast microbubbles in imaging and therapy: physical principles and engineering. Phys Med Biol (2009) 2.27
Radiation-force assisted targeting facilitates ultrasonic molecular imaging. Mol Imaging (2004) 2.19
Direct observations of ultrasound microbubble contrast agent interaction with the microvessel wall. J Acoust Soc Am (2007) 2.11
[Scandinavian guidelines for prehospital management of severe traumatic brain injury]. Tidsskr Nor Laegeforen (2008) 2.03
Spherical nucleic acid nanoparticle conjugates as an RNAi-based therapy for glioblastoma. Sci Transl Med (2013) 1.99
Bioresponsive, cell-penetrating, and multimeric MR contrast agents. Acc Chem Res (2009) 1.94
Acoustic response of compliable microvessels containing ultrasound contrast agents. Phys Med Biol (2006) 1.91
Targeted imaging using ultrasound. J Magn Reson Imaging (2002) 1.88
Multimodal MRI contrast agents. J Biol Inorg Chem (2007) 1.86
Enhancement of vascular permeability with low-frequency contrast-enhanced ultrasound in the chorioallantoic membrane model. Radiology (2007) 1.86
Mapping transplanted stem cell migration after a stroke: a serial, in vivo magnetic resonance imaging study. Neuroimage (2004) 1.86
Tracking transplanted stem cell migration using bifunctional, contrast agent-enhanced, magnetic resonance imaging. Neuroimage (2002) 1.82
A method for radiation-force localized drug delivery using gas-filled lipospheres. IEEE Trans Ultrason Ferroelectr Freq Control (2004) 1.79
Motion corrected cadence CPS ultrasound for quantifying response to vasoactive drugs in a rat kidney model. Urology (2009) 1.78
Influence of lipid shell physicochemical properties on ultrasound-induced microbubble destruction. IEEE Trans Ultrason Ferroelectr Freq Control (2005) 1.77
Therapeutic effects of paclitaxel-containing ultrasound contrast agents. Ultrasound Med Biol (2006) 1.75
Angiopoietin-2 promotes myeloid cell infiltration in a β₂-integrin-dependent manner. Blood (2011) 1.73
Acoustically-active microbubbles conjugated to liposomes: characterization of a proposed drug delivery vehicle. J Control Release (2006) 1.70
Changes in bone resorption across the menopause transition: effects of reproductive hormones, body size, and ethnicity. J Clin Endocrinol Metab (2013) 1.69
Ultrasound radiation force enables targeted deposition of model drug carriers loaded on microbubbles. J Control Release (2005) 1.68
Epoxy metabolites of docosahexaenoic acid (DHA) inhibit angiogenesis, tumor growth, and metastasis. Proc Natl Acad Sci U S A (2013) 1.66
The synthesis and in vitro testing of a zinc-activated MRI contrast agent. Proc Natl Acad Sci U S A (2007) 1.65
Ultrasound molecular imaging of tumor angiogenesis with an integrin targeted microbubble contrast agent. Invest Radiol (2011) 1.64
Mechanistic studies of a calcium-dependent MRI contrast agent. Inorg Chem (2002) 1.64
Long-circulating liposomes radiolabeled with [18F]fluorodipalmitin ([18F]FDP). Nucl Med Biol (2007) 1.60
Enhanced in vivo bioluminescence imaging using liposomal luciferin delivery system. J Control Release (2009) 1.60
Self-assembled peptide amphiphile nanofibers conjugated to MRI contrast agents. Nano Lett (2005) 1.59
Life disruptions for midlife and older adults with high out-of-pocket health expenditures. Ann Fam Med (2013) 1.57
In vivo animal models for studying brain metastasis: value and limitations. Clin Exp Metastasis (2013) 1.52
Mutation-specific IDH1 antibody differentiates oligodendrogliomas and oligoastrocytomas from other brain tumors with oligodendroglioma-like morphology. Acta Neuropathol (2010) 1.52
Lateral phase separation in lipid-coated microbubbles. Langmuir (2006) 1.52
A systematic review and meta-synthesis: evaluating the effectiveness of nurse, midwife/allied health professional consultants. J Clin Nurs (2007) 1.52
Gd(III)-nanodiamond conjugates for MRI contrast enhancement. Nano Lett (2010) 1.50
Synthesis of multimeric MR contrast agents for cellular imaging. J Am Chem Soc (2008) 1.49
Ultrasonic analysis of peptide- and antibody-targeted microbubble contrast agents for molecular imaging of alphavbeta3-expressing cells. Mol Imaging (2004) 1.49
Multimodal gadolinium-enriched DNA-gold nanoparticle conjugates for cellular imaging. Angew Chem Int Ed Engl (2009) 1.47
Targeted imaging using ultrasound contrast agents. Progess and opportunities for clinical and research applications. IEEE Eng Med Biol Mag (2004) 1.46
Prevalence of and risk factors for chronic kidney disease in rural Nicaragua. Nephrol Dial Transplant (2010) 1.46
Exome sequencing can detect pathogenic mosaic mutations present at low allele frequencies. J Hum Genet (2011) 1.45
PSA enzymatic activity: a new biomarker for assessing prostate cancer aggressiveness. Prostate (2013) 1.43
Application of ultrasound to selectively localize nanodroplets for targeted imaging and therapy. Mol Imaging (2006) 1.43
A modular system for the synthesis of multiplexed magnetic resonance probes. J Am Chem Soc (2011) 1.40
A novel method to label preformed liposomes with 64Cu for positron emission tomography (PET) imaging. Bioconjug Chem (2008) 1.39
Contrast-enhanced US of microcirculation of superficially implanted tumors in rats. Radiology (2003) 1.38
Expression of extracellular matrix components in a highly infiltrative in vivo glioma model. Acta Neuropathol (2002) 1.35
Imaging of angiogenesis using Cadence contrast pulse sequencing and targeted contrast agents. Contrast Media Mol Imaging (2008) 1.34
Lanthanide probes for bioresponsive imaging. Chem Rev (2013) 1.34
Dynamics of therapeutic ultrasound contrast agents. Ultrasound Med Biol (2002) 1.32
The natural frequency of nonlinear oscillation of ultrasound contrast agents in microvessels. Ultrasound Med Biol (2007) 1.30
Magnetic resonance imaging of self-assembled biomaterial scaffolds. Bioconjug Chem (2005) 1.29
Effect of coupled oscillations on microbubble behavior. J Acoust Soc Am (2003) 1.29
Monitoring intraurban spatial patterns of multiple combustion air pollutants in New York City: design and implementation. J Expo Sci Environ Epidemiol (2013) 1.28
Promoting informed choice: evaluating a decision-making tool for family planning clients and providers in Mexico. Int Fam Plan Perspect (2005) 1.27
Differential utilization of ketone bodies by neurons and glioma cell lines: a rationale for ketogenic diet as experimental glioma therapy. BMC Cancer (2011) 1.25
Mechanistic investigation of beta-galactosidase-activated MR contrast agents. Inorg Chem (2007) 1.24
Glioma cell populations grouped by different cell type markers drive brain tumor growth. Cancer Res (2010) 1.24
Ultrasound radiation force modulates ligand availability on targeted contrast agents. Mol Imaging (2006) 1.23
The in vitro effects of a bimodal contrast agent on cellular functions and relaxometry. NMR Biomed (2007) 1.23
Intra-urban spatial variability in wintertime street-level concentrations of multiple combustion-related air pollutants: the New York City Community Air Survey (NYCCAS). J Expo Sci Environ Epidemiol (2013) 1.22
A stimulus-responsive contrast agent for ultrasound molecular imaging. Biomaterials (2007) 1.22
Cellular delivery of MRI contrast agents. Chem Biol (2004) 1.20
DNA-TiO2 nanoconjugates labeled with magnetic resonance contrast agents. J Am Chem Soc (2007) 1.19
Reporter protein-targeted probes for magnetic resonance imaging. J Am Chem Soc (2011) 1.18
Contrast-enhanced computed tomography and ultrasound for the evaluation of tumor blood flow. Invest Radiol (2005) 1.17
A new imaging strategy using wideband transient response of ultrasound contrast agents. IEEE Trans Ultrason Ferroelectr Freq Control (2005) 1.17
A radio-frequency coupling network for heating of citrate-coated gold nanoparticles for cancer therapy: design and analysis. IEEE Trans Biomed Eng (2011) 1.17
Dynamic microPET imaging of ultrasound contrast agents and lipid delivery. J Control Release (2008) 1.16
DNA and polylysine adsorption and multilayer construction onto cationic lipid-coated microbubbles. Langmuir (2007) 1.16
A gadolinium chelate for detection of beta-glucuronidase: a self-immolative approach. J Am Chem Soc (2005) 1.16
Targeted inhibition of Snail family zinc finger transcription factors by oligonucleotide-Co(III) Schiff base conjugate. Proc Natl Acad Sci U S A (2009) 1.15
Mechanisms of ZnII-activated magnetic resonance imaging agents. Inorg Chem (2008) 1.14
Targeting activin receptor-like kinase 1 inhibits angiogenesis and tumorigenesis through a mechanism of action complementary to anti-VEGF therapies. Cancer Res (2011) 1.13
EGFR wild-type amplification and activation promote invasion and development of glioblastoma independent of angiogenesis. Acta Neuropathol (2013) 1.13
Ultrasound increases nanoparticle delivery by reducing intratumoral pressure and increasing transport in epithelial and epithelial-mesenchymal transition tumors. Cancer Res (2012) 1.12
Spatial and temporal-controlled tissue heating on a modified clinical ultrasound scanner for generating mild hyperthermia in tumors. IEEE Trans Biomed Eng (2010) 1.12
Asymmetric oscillation of adherent targeted ultrasound contrast agents. Appl Phys Lett (2005) 1.12
Acoustic response from adherent targeted contrast agents. J Acoust Soc Am (2006) 1.11
EGFL7 ligates αvβ3 integrin to enhance vessel formation. Blood (2013) 1.11
Efficient array design for sonotherapy. Phys Med Biol (2008) 1.07
MicroRNA regulation of the synaptic plasticity-related gene Arc. PLoS One (2012) 1.07
Quantitative evaluation of perfusion and permeability of peripheral tumors using contrast-enhanced computed tomography. Invest Radiol (2004) 1.07
Dynamics and fragmentation of thick-shelled microbubbles. IEEE Trans Ultrason Ferroelectr Freq Control (2002) 1.07
A novel nonsense CDK5RAP2 mutation in a Somali child with primary microcephaly and sensorineural hearing loss. Am J Med Genet A (2012) 1.06
Ultrasound-driven microbubble oscillation and translation within small phantom vessels. Ultrasound Med Biol (2007) 1.05
An imaging-driven model for liposomal stability and circulation. Mol Pharm (2010) 1.05
Angiogenic response to bioactive glass promotes bone healing in an irradiated calvarial defect. Tissue Eng Part A (2009) 1.05
Targeted inactivation of Snail family EMT regulatory factors by a Co(III)-Ebox conjugate. PLoS One (2012) 1.05
Targeting the NG2/CSPG4 proteoglycan retards tumour growth and angiogenesis in preclinical models of GBM and melanoma. PLoS One (2011) 1.05
Survivin inhibition and DNA double-strand break repair: a molecular mechanism to overcome radioresistance in glioblastoma. Radiother Oncol (2011) 1.05
Bevacizumab treatment induces metabolic adaptation toward anaerobic metabolism in glioblastomas. Acta Neuropathol (2014) 1.04
In vitro transdermal delivery of caffeine, theobromine, theophylline and catechin from extract of Guarana, Paullinia Cupana. Int J Pharm (2006) 1.04